These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 23788571)

  • 41. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity.
    Veronese FM; Schiavon O; Pasut G; Mendichi R; Andersson L; Tsirk A; Ford J; Wu G; Kneller S; Davies J; Duncan R
    Bioconjug Chem; 2005; 16(4):775-84. PubMed ID: 16029018
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety of PEGylated recombinant human full-length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates.
    Stidl R; Fuchs S; Bossard M; Siekmann J; Turecek PL; Putz M
    Haemophilia; 2016 Jan; 22(1):54-64. PubMed ID: 26219204
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nonclinical Safety Assessment of a Long-Acting Recombinant PEGylated Factor Eight (BAY 94-9027) With a 60 kDa PEG.
    Ivens IA; Banczyk D; Gutberlet K; Jackman S; Vauléon S; Frisk AL
    Toxicol Pathol; 2019 Jul; 47(5):585-597. PubMed ID: 31132933
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Subchronic intravenous toxicity studies with gamma-cyclodextrin in rats.
    Donaubauer HH; Fuchs H; Langer KH; Bär A
    Regul Toxicol Pharmacol; 1998 Apr; 27(2):189-98. PubMed ID: 9671574
    [TBL] [Abstract][Full Text] [Related]  

  • 45. GEMMA and MALDI-TOF MS of reactive PEGs for pharmaceutical applications.
    Kemptner J; Marchetti-Deschmann M; Siekmann J; Turecek PL; Schwarz HP; Allmaier G
    J Pharm Biomed Anal; 2010 Aug; 52(4):432-7. PubMed ID: 20138456
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration.
    Abu Lila AS; Nawata K; Shimizu T; Ishida T; Kiwada H
    Int J Pharm; 2013 Nov; 456(1):235-42. PubMed ID: 23928149
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Measurements of intestinal permeability using low molecular weight polyethylene glycols (PEG 400). I. Chemical analysis and biological properties of PEG 400.
    Chadwick VS; Phillips SF; Hofmann AF
    Gastroenterology; 1977 Aug; 73(2):241-6. PubMed ID: 873124
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Polyethylene glycol conjugation at Cys232 prolongs the half-life of alpha1 proteinase inhibitor.
    Cantin AM; Woods DE; Cloutier D; Dufour EK; Leduc R
    Am J Respir Cell Mol Biol; 2002 Dec; 27(6):659-65. PubMed ID: 12444025
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Assessment of Labrasol/Labrafil/Transcutol (4/4/2, v/v/v) as a non-clinical vehicle for poorly water-soluble compounds after 4-week oral toxicity study in Wistar rats.
    Delongeas JL; de Conchard GV; Beamonte A; Bertheux H; Spire C; Maisonneuve C; Becourt-Lhote N; Goldfain-Blanc F; Claude N
    Regul Toxicol Pharmacol; 2010; 57(2-3):284-90. PubMed ID: 20347907
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of polyols on polyethylene glycol (PEG)-induced precipitation of proteins: Impact on solubility, stability and conformation.
    Kumar V; Sharma VK; Kalonia DS
    Int J Pharm; 2009 Jan; 366(1-2):38-43. PubMed ID: 18809481
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes.
    Malek A; Merkel O; Fink L; Czubayko F; Kissel T; Aigner A
    Toxicol Appl Pharmacol; 2009 Apr; 236(1):97-108. PubMed ID: 19371615
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of poly(ethylene glycol) conjugated lactoferrin for oral administration.
    Nojima Y; Suzuki Y; Iguchi K; Shiga T; Iwata A; Fujimoto T; Yoshida K; Shimizu H; Takeuchi T; Sato A
    Bioconjug Chem; 2008 Nov; 19(11):2253-9. PubMed ID: 18834167
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Polyethylene glycol conjugation of recombinant methioninase for cancer therapy.
    Tan Y; Sun X; Xu M; An Z; Tan X; Han Q; Miljkovic DA; Yang M; Hoffman RM
    Protein Expr Purif; 1998 Feb; 12(1):45-52. PubMed ID: 9473456
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of Solutol (Kolliphor) and cremophor in polyethylene glycol 400 vehicle formulations in Sprague-Dawley rats and beagle dogs.
    Stokes AH; Kemp DC; Faiola B; Jordan HL; Merrill CL; Hailey JR; Brown RE; Bailey DW
    Int J Toxicol; 2013; 32(3):189-97. PubMed ID: 23616145
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Separation and detection of bis-maleimide-polyethylene glycol and mono-maleimide-polyethylene glycol by reversed-phase high pressure liquid chromatography.
    Tang L; Jariwala F; Bolgar M; Lloyd DK
    J Chromatogr A; 2012 Jul; 1246():117-22. PubMed ID: 22503616
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Selectivity of binding of PEGs and PEG-like oligomers to anti-PEG antibodies induced by methoxyPEG-proteins.
    Saifer MG; Williams LD; Sobczyk MA; Michaels SJ; Sherman MR
    Mol Immunol; 2014 Feb; 57(2):236-46. PubMed ID: 24200843
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The ability of polyethylene glycol conjugated bovine hemoglobin (PEG-Hb) to adequately deliver oxygen in both exchange transfusion and top-loaded rat models.
    Conover CD; Linberg R; Shum KL; Shorr RG
    Artif Cells Blood Substit Immobil Biotechnol; 1999 Mar; 27(2):93-107. PubMed ID: 10092932
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Liquid chromatography/tandem mass spectrometry method for quantitative estimation of polyethylene glycol 400 and its applications.
    Vijaya Bhaskar V; Middha A; Tiwari S; Shivakumar S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 May; 926():68-76. PubMed ID: 23545562
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Size-dependent permeability of hydrophilic probes across rabbit colonic epithelium.
    Ghandehari H; Smith PL; Ellens H; Yeh PY; Kopecek J
    J Pharmacol Exp Ther; 1997 Feb; 280(2):747-53. PubMed ID: 9023287
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development.
    Ivens IA; Achanzar W; Baumann A; Brändli-Baiocco A; Cavagnaro J; Dempster M; Depelchin BO; Rovira AR; Dill-Morton L; Lane JH; Reipert BM; Salcedo T; Schweighardt B; Tsuruda LS; Turecek PL; Sims J
    Toxicol Pathol; 2015 Oct; 43(7):959-83. PubMed ID: 26239651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.